Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 16 | 2024 | 1023 | 2.330 |
Why?
|
| Lung Transplantation | 10 | 2024 | 316 | 1.740 |
Why?
|
| Extracorporeal Membrane Oxygenation | 10 | 2022 | 628 | 1.520 |
Why?
|
| Heart Transplantation | 6 | 2022 | 854 | 1.390 |
Why?
|
| Heart Failure | 12 | 2024 | 2125 | 1.270 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2024 | 193 | 0.940 |
Why?
|
| Catheterization, Central Venous | 2 | 2012 | 130 | 0.710 |
Why?
|
| Hepatitis C | 2 | 2017 | 365 | 0.700 |
Why?
|
| Device Removal | 1 | 2020 | 223 | 0.630 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 8 | 0.590 |
Why?
|
| Fluorenes | 1 | 2017 | 7 | 0.590 |
Why?
|
| Benzimidazoles | 1 | 2017 | 128 | 0.540 |
Why?
|
| Hepacivirus | 1 | 2017 | 241 | 0.510 |
Why?
|
| Tissue and Organ Procurement | 3 | 2015 | 218 | 0.500 |
Why?
|
| Preoperative Care | 1 | 2017 | 350 | 0.490 |
Why?
|
| Shock, Cardiogenic | 3 | 2021 | 189 | 0.470 |
Why?
|
| Resource Allocation | 1 | 2014 | 52 | 0.470 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2024 | 78 | 0.450 |
Why?
|
| Tissue Donors | 6 | 2020 | 496 | 0.450 |
Why?
|
| Polytetrafluoroethylene | 2 | 2019 | 80 | 0.410 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2012 | 2 | 0.410 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 155 | 0.400 |
Why?
|
| Antiviral Agents | 1 | 2017 | 740 | 0.400 |
Why?
|
| Takayasu Arteritis | 1 | 2012 | 13 | 0.400 |
Why?
|
| Lung Diseases | 2 | 2019 | 385 | 0.390 |
Why?
|
| Anastomotic Leak | 1 | 2012 | 27 | 0.390 |
Why?
|
| Peritoneal Cavity | 1 | 2011 | 18 | 0.390 |
Why?
|
| Reoperation | 3 | 2024 | 819 | 0.390 |
Why?
|
| Embolism | 1 | 2011 | 49 | 0.380 |
Why?
|
| Middle Aged | 24 | 2024 | 25980 | 0.380 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 175 | 0.370 |
Why?
|
| Ventricular Function, Right | 1 | 2012 | 112 | 0.370 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2011 | 75 | 0.370 |
Why?
|
| Retrospective Studies | 20 | 2024 | 15981 | 0.360 |
Why?
|
| Thrombosis | 3 | 2022 | 520 | 0.330 |
Why?
|
| Heart Atria | 1 | 2011 | 310 | 0.320 |
Why?
|
| Humans | 48 | 2024 | 123199 | 0.310 |
Why?
|
| Adult | 20 | 2024 | 29038 | 0.310 |
Why?
|
| Survival Rate | 5 | 2019 | 1995 | 0.280 |
Why?
|
| Aorta, Thoracic | 1 | 2012 | 517 | 0.280 |
Why?
|
| Ischemia | 2 | 2024 | 337 | 0.280 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2021 | 366 | 0.270 |
Why?
|
| Female | 27 | 2024 | 65432 | 0.270 |
Why?
|
| Follow-Up Studies | 6 | 2024 | 5048 | 0.270 |
Why?
|
| Staphylococcal Infections | 1 | 2011 | 553 | 0.270 |
Why?
|
| Vascular Surgical Procedures | 1 | 2012 | 565 | 0.270 |
Why?
|
| Male | 27 | 2024 | 60021 | 0.260 |
Why?
|
| Graft Rejection | 2 | 2019 | 582 | 0.250 |
Why?
|
| Ohio | 3 | 2014 | 89 | 0.240 |
Why?
|
| Lung | 4 | 2024 | 1469 | 0.240 |
Why?
|
| Treatment Outcome | 13 | 2024 | 12103 | 0.230 |
Why?
|
| Cystic Fibrosis | 2 | 2019 | 257 | 0.220 |
Why?
|
| Subclavian Vein | 2 | 2012 | 23 | 0.210 |
Why?
|
| Heparin | 3 | 2013 | 229 | 0.210 |
Why?
|
| Mitral Valve | 1 | 2024 | 246 | 0.200 |
Why?
|
| Catheterization | 3 | 2012 | 234 | 0.200 |
Why?
|
| Anticoagulants | 4 | 2022 | 585 | 0.200 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2023 | 92 | 0.200 |
Why?
|
| Hyponatremia | 1 | 2022 | 70 | 0.190 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2024 | 425 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 6 | 2005 | 688 | 0.180 |
Why?
|
| Tracheostomy | 2 | 2023 | 191 | 0.180 |
Why?
|
| Aged | 10 | 2024 | 19072 | 0.170 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 141 | 0.170 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2024 | 1102 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 3 | 2005 | 37 | 0.160 |
Why?
|
| Hemorrhage | 2 | 2019 | 459 | 0.160 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 233 | 0.150 |
Why?
|
| Medical Overuse | 1 | 2018 | 27 | 0.150 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 114 | 0.150 |
Why?
|
| Incidence | 4 | 2024 | 3050 | 0.150 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 149 | 0.150 |
Why?
|
| Acute Lung Injury | 1 | 2018 | 62 | 0.150 |
Why?
|
| Allografts | 1 | 2018 | 190 | 0.150 |
Why?
|
| Sofosbuvir | 1 | 2017 | 13 | 0.150 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2019 | 164 | 0.150 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 229 | 0.140 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 500 | 0.140 |
Why?
|
| Echocardiography | 3 | 2011 | 1070 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 2043 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 623 | 0.130 |
Why?
|
| Phenylalanine | 4 | 2000 | 120 | 0.130 |
Why?
|
| Thiophenes | 4 | 2000 | 60 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2018 | 302 | 0.130 |
Why?
|
| Graft Survival | 3 | 2020 | 525 | 0.130 |
Why?
|
| Equipment Design | 2 | 2021 | 600 | 0.130 |
Why?
|
| Metalloendopeptidases | 3 | 2000 | 101 | 0.120 |
Why?
|
| Pulmonary Heart Disease | 1 | 2014 | 4 | 0.120 |
Why?
|
| Prognosis | 4 | 2021 | 4509 | 0.120 |
Why?
|
| Bacteria | 1 | 2018 | 483 | 0.120 |
Why?
|
| Compartment Syndromes | 1 | 2014 | 31 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2013 | 357 | 0.110 |
Why?
|
| Death | 1 | 2015 | 71 | 0.110 |
Why?
|
| Extremities | 1 | 2014 | 82 | 0.110 |
Why?
|
| Young Adult | 5 | 2019 | 8869 | 0.110 |
Why?
|
| Time Factors | 5 | 2021 | 6201 | 0.110 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2014 | 133 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1005 | 0.110 |
Why?
|
| Donor Selection | 1 | 2013 | 52 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2012 | 96 | 0.100 |
Why?
|
| Axillary Artery | 1 | 2012 | 27 | 0.100 |
Why?
|
| Drug Overdose | 1 | 2013 | 65 | 0.100 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2012 | 50 | 0.100 |
Why?
|
| Jugular Veins | 1 | 2012 | 72 | 0.100 |
Why?
|
| Aneurysm, Ruptured | 1 | 2011 | 36 | 0.100 |
Why?
|
| Coronary Aneurysm | 1 | 2011 | 34 | 0.090 |
Why?
|
| Equipment Failure | 1 | 2011 | 123 | 0.090 |
Why?
|
| Matrix Metalloproteinase 2 | 5 | 2005 | 94 | 0.090 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2011 | 44 | 0.090 |
Why?
|
| Catheters, Indwelling | 1 | 2012 | 156 | 0.090 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2012 | 112 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 1306 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2397 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2012 | 338 | 0.090 |
Why?
|
| Adenocarcinoma | 3 | 2005 | 991 | 0.090 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2012 | 246 | 0.090 |
Why?
|
| End Stage Liver Disease | 1 | 2012 | 177 | 0.090 |
Why?
|
| Liver Function Tests | 1 | 2010 | 101 | 0.090 |
Why?
|
| Fibroma | 1 | 2010 | 30 | 0.090 |
Why?
|
| Hospitals | 2 | 2023 | 397 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 2012 | 172 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 234 | 0.090 |
Why?
|
| Gelatinases | 2 | 1999 | 14 | 0.080 |
Why?
|
| Heart Neoplasms | 1 | 2010 | 101 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 359 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 1872 | 0.080 |
Why?
|
| Protease Inhibitors | 2 | 1999 | 95 | 0.080 |
Why?
|
| Pulmonary Artery | 1 | 2012 | 439 | 0.080 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 524 | 0.080 |
Why?
|
| Stroke Volume | 1 | 2010 | 449 | 0.080 |
Why?
|
| Transfection | 3 | 2005 | 1068 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 431 | 0.070 |
Why?
|
| Mortality | 2 | 2019 | 230 | 0.070 |
Why?
|
| Risk Factors | 4 | 2024 | 10001 | 0.070 |
Why?
|
| DNA, Antisense | 1 | 2005 | 8 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2024 | 3007 | 0.060 |
Why?
|
| Neoplasm Transplantation | 5 | 2005 | 369 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1013 | 0.060 |
Why?
|
| Heart Arrest, Induced | 1 | 2024 | 73 | 0.060 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2000 | 18 | 0.050 |
Why?
|
| Mice, Nude | 5 | 2005 | 692 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2010 | 819 | 0.050 |
Why?
|
| Gene Expression | 3 | 2005 | 1569 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2023 | 3332 | 0.050 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 161 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2019 | 1167 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2010 | 998 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 5 | 2002 | 1063 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2002 | 240 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2010 | 1684 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1257 | 0.040 |
Why?
|
| Mean Platelet Volume | 1 | 2019 | 3 | 0.040 |
Why?
|
| I-kappa B Proteins | 1 | 1999 | 41 | 0.040 |
Why?
|
| Macrophages, Peritoneal | 1 | 1999 | 38 | 0.040 |
Why?
|
| Polymyxins | 1 | 2019 | 14 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 649 | 0.040 |
Why?
|
| Collagenases | 1 | 1999 | 18 | 0.040 |
Why?
|
| Shock, Hemorrhagic | 1 | 1999 | 50 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 1470 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1004 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2022 | 767 | 0.040 |
Why?
|
| Shock, Septic | 1 | 1999 | 148 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 330 | 0.040 |
Why?
|
| NF-kappa B | 1 | 1999 | 459 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 313 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 455 | 0.030 |
Why?
|
| Blotting, Western | 3 | 2005 | 1102 | 0.030 |
Why?
|
| Organ Preservation | 1 | 2015 | 36 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 1390 | 0.030 |
Why?
|
| Texas | 1 | 2022 | 3548 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1684 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 180 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 1231 | 0.030 |
Why?
|
| Animals | 9 | 2012 | 33741 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2015 | 224 | 0.030 |
Why?
|
| Reperfusion | 1 | 2012 | 25 | 0.030 |
Why?
|
| Mice | 7 | 2005 | 17498 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3260 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2022 | 6028 | 0.020 |
Why?
|
| Acute Disease | 1 | 2014 | 1090 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2012 | 188 | 0.020 |
Why?
|
| Perfusion | 1 | 2012 | 197 | 0.020 |
Why?
|
| Quality of Life | 1 | 2021 | 1932 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 730 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2005 | 602 | 0.020 |
Why?
|
| Endocardial Fibroelastosis | 1 | 2010 | 11 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 130 | 0.020 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2010 | 87 | 0.020 |
Why?
|
| Chest Pain | 1 | 2010 | 126 | 0.020 |
Why?
|
| Swine | 1 | 2012 | 1155 | 0.020 |
Why?
|
| Dyspnea | 1 | 2010 | 149 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2010 | 241 | 0.020 |
Why?
|
| Oxygen | 1 | 2012 | 540 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 19086 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2010 | 418 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 4268 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2000 | 1002 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2801 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2010 | 961 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 511 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2002 | 2820 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 1069 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 123 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2002 | 77 | 0.010 |
Why?
|
| Pancreas | 1 | 2002 | 210 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2000 | 70 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 779 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2000 | 280 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2000 | 77 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 230 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2000 | 211 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 426 | 0.010 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 1999 | 3 | 0.010 |
Why?
|
| Survival | 1 | 1999 | 19 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 1999 | 34 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1999 | 172 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 696 | 0.010 |
Why?
|
| Cytosol | 1 | 1999 | 159 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 815 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 1999 | 137 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 3289 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2308 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1999 | 619 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1999 | 291 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1999 | 674 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 670 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 1211 | 0.010 |
Why?
|
| Body Weight | 1 | 2000 | 999 | 0.010 |
Why?
|
| Apoptosis | 1 | 2002 | 1783 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1695 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1999 | 3050 | 0.010 |
Why?
|
| Rats | 1 | 1999 | 3631 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2002 | 1305 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1999 | 2048 | 0.010 |
Why?
|
| Signal Transduction | 1 | 1999 | 4508 | 0.000 |
Why?
|